Abstracts tagged "SLE and antiphospholipid antibodies"

Abstract Number: 716 • 2017 ACR/ARHP Annual Meeting
Prolonged Exposure to Antiphospholipid Antibodies Is Associated with Endothelial Dysfunction in Patients with Systemic Lupus Erythematosus
In-Woon Baek¹, Yune-Jung Park², Ki-Jo Kim³, Wan-Uk Kim Sr.⁴ and Chul-Soo Cho¹, ¹Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Gyeonggido, Korea, Republic of (South), ³Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South), ⁴The Catholic University of Korea, Department of Internal Medicine, seoul, Korea, Republic of (South)
Background/Purpose: Antiphospholipid syndrome has been shown to be associated with increased cardiovascular mortality, but the role of antiphospholipid antibodies (aPL) on endothelial dysfunction remains elusive.…
Abstract Number: 2098 • 2016 ACR/ARHP Annual Meeting
Non-Criteria Anti-Phospholipid Antibodies in SLE Patients
Lidia Ostanek¹, Danuta Bobrowska-Snarska¹, Katarzyna Fischer² and Marek Brzosko¹, ¹Department of Rheumatology and Internal Medicine and Geriatrics, Pomeranian Medical University, Szczecin, Poland, ²Independent Laboratory of Rheumatologic Diagnostics, Pomeranian Medical University, Szczecin, Poland
Background/Purpose: Current classification criteria for definite antiphospholipid syndrome (APS) recommend the use of one or more of three positive standardized laboratory assays, including anticardiolipin antibodies,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].